Skip to main content
Erschienen in: Diabetologia 2/2012

01.02.2012 | Article

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

verfasst von: I. Vermeulen, I. Weets, O. Costa, M. Asanghanwa, K. Verhaeghen, K. Decochez, J. Ruige, K. Casteels, J. Wenzlau, J. C. Hutton, D. G. Pipeleers, F. K. Gorus, the Belgian Diabetes Registry

Erschienen in: Diabetologia | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The appearance of autoantibodies (Abs) before diabetes onset has mainly been studied in young children. However, most patients develop type 1 diabetes after the age of 15 years. In first-degree relatives aged under 40 years, we investigated the frequency of seroconversion to (persistent) Ab positivity, progression to diabetes and baseline characteristics of seroconverters according to age.

Methods

Abs against insulin (IAA), glutamate decarboxylase (GADA), insulinoma-associated protein 2 (IA-2A) and zinc transporter 8 (ZnT8A) were measured during follow-up of 7,170 first-degree relatives.

Results

We identified 379 (5.3%) relatives with positivity for IAA, GADA, IA-2A and/or ZnT8A (Ab+) at first sampling and 224 (3.1%) at a later time point. Most seroconversions occurred after the age of 10 years (63%). During follow-up, Abs persisted more often in relatives initially Ab+ (76%) than in seroconverters (53%; p < 0.001). In both groups diabetes developed at a similar pace and almost exclusively with Ab persistence (136 of 139 prediabetic individuals). For both groups, progression was more rapid if Abs appeared before the age of 10 years. Baseline characteristics at seroconversion did not vary significantly according to age.

Conclusions/interpretation

Seroconversion to (persistent) Ab+ occurs regardless of age. Although the progression rate to diabetes is higher under age 10 years, later seroconverters (up to age 40 years) have similar characteristics when compared with age-matched initially Ab+ relatives and generate an important minority of prediabetic relatives, warranting their identification and, eventually, enrolment in prevention trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Leslie RD, Delli Castelli M (2004) Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53:3033–3040PubMedCrossRef Leslie RD, Delli Castelli M (2004) Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 53:3033–3040PubMedCrossRef
2.
Zurück zum Zitat Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMedCrossRef Pipeleers D, Ling Z (1992) Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8:209–227PubMedCrossRef
3.
Zurück zum Zitat Gorus FK (1997) Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 13:247–274PubMedCrossRef Gorus FK (1997) Diabetes registries and early biological markers of insulin-dependent diabetes mellitus. Belgian Diabetes Registry. Diabetes Metab Rev 13:247–274PubMedCrossRef
4.
Zurück zum Zitat Skyler JS, Ricordi C (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 60:1–8PubMedCrossRef Skyler JS, Ricordi C (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 60:1–8PubMedCrossRef
5.
Zurück zum Zitat Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRef Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRef
6.
Zurück zum Zitat Gorus FK, Pipeleers DG (2001) Prospects for predicting and stopping the development of type 1 of diabetes. The Belgian Diabetes Registry. Best Pract Res Clin Endocrinol Metab 15:371–389PubMedCrossRef Gorus FK, Pipeleers DG (2001) Prospects for predicting and stopping the development of type 1 of diabetes. The Belgian Diabetes Registry. Best Pract Res Clin Endocrinol Metab 15:371–389PubMedCrossRef
7.
Zurück zum Zitat Vandewalle CL, Coeckelberghs MI, de Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 20:1556–1561PubMedCrossRef Vandewalle CL, Coeckelberghs MI, de Leeuw IH et al (1997) Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry. Diabetes Care 20:1556–1561PubMedCrossRef
8.
Zurück zum Zitat Kyvik K, Nyström L, Gorus F et al (2004) The epidemiology of type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 47:377–384PubMedCrossRef Kyvik K, Nyström L, Gorus F et al (2004) The epidemiology of type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 47:377–384PubMedCrossRef
9.
Zurück zum Zitat Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef Ziegler AG, Hummel M, Schenker M, Bonifacio E (1999) Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. Diabetes 48:460–468PubMedCrossRef
10.
Zurück zum Zitat Kimpimäki T, Kupila A, Hämäläinen A-M et al (2001) The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish type 1 prediction and prevention study. J Clin Endocrinol Metab 86:4782–4788PubMedCrossRef Kimpimäki T, Kupila A, Hämäläinen A-M et al (2001) The first signs of β-cell autoimmunity appear in infancy in genetically susceptible children from the general population: the Finnish type 1 prediction and prevention study. J Clin Endocrinol Metab 86:4782–4788PubMedCrossRef
11.
Zurück zum Zitat Rewers M, Norris JM, Eisenbarth GS et al (1996) Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 9:405–410PubMedCrossRef Rewers M, Norris JM, Eisenbarth GS et al (1996) Beta-cell autoantibodies in infants and toddlers without IDDM relatives: Diabetes Autoimmunity Study in the Young (DAISY). J Autoimmun 9:405–410PubMedCrossRef
12.
Zurück zum Zitat Carmichael SK, Johnson SB, Baughcum A et al (2003) Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 5:77–83PubMedCrossRef Carmichael SK, Johnson SB, Baughcum A et al (2003) Prospective assessment in newborns of diabetes autoimmunity (PANDA): maternal understanding of infant diabetes risk. Genet Med 5:77–83PubMedCrossRef
13.
Zurück zum Zitat TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1–13CrossRef TEDDY Study Group (2008) The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann NY Acad Sci 1150:1–13CrossRef
14.
Zurück zum Zitat Knip M, Korhonen S, Kulmala P et al (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206–1212PubMedCrossRef Knip M, Korhonen S, Kulmala P et al (2010) Prediction of type 1 diabetes in the general population. Diabetes Care 33:1206–1212PubMedCrossRef
15.
Zurück zum Zitat Simell O, Winter WE, Schatz D (2010) Enhancing the understanding of pre-type 1 diabetes in the general population. Diabetes Care 33:1403–1405PubMedCrossRef Simell O, Winter WE, Schatz D (2010) Enhancing the understanding of pre-type 1 diabetes in the general population. Diabetes Care 33:1403–1405PubMedCrossRef
16.
Zurück zum Zitat De Grijse J, Asanghanwa M, Nouthe B et al (2010) Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53:517–524PubMedCrossRef De Grijse J, Asanghanwa M, Nouthe B et al (2010) Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials. Diabetologia 53:517–524PubMedCrossRef
17.
Zurück zum Zitat Truyen I, de Pauw P, Jørgensen P et al (2005) Proinsulin levels and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48:2322–2329PubMedCrossRef Truyen I, de Pauw P, Jørgensen P et al (2005) Proinsulin levels and proinsulin-to-C-peptide ratio complement autoantibody measurement for predicting type 1 diabetes. Diabetologia 48:2322–2329PubMedCrossRef
18.
Zurück zum Zitat Van der Auwera BJ, Schuit FC, Weets I et al (2002) Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for further prevention studies. The Belgian Diabetes Registry. Hum Immunol 63:40–50PubMedCrossRef Van der Auwera BJ, Schuit FC, Weets I et al (2002) Relative and absolute HLA-DQA1-DQB1 linked risk for developing type I diabetes before 40 years of age in the Belgian population: implications for further prevention studies. The Belgian Diabetes Registry. Hum Immunol 63:40–50PubMedCrossRef
19.
Zurück zum Zitat Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045PubMedCrossRef Wenzlau JM, Juhl K, Yu L et al (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA 104:17040–17045PubMedCrossRef
20.
Zurück zum Zitat Achenbach P, Bonifacio E, Koczwara K, Ziegler A (2005) Natural history of type 1 diabetes. Diabetes 53(Suppl 2):S25–S31CrossRef Achenbach P, Bonifacio E, Koczwara K, Ziegler A (2005) Natural history of type 1 diabetes. Diabetes 53(Suppl 2):S25–S31CrossRef
21.
Zurück zum Zitat Jasinski JM, Eisenbarth GS (2005) Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 12:181–186PubMedCrossRef Jasinski JM, Eisenbarth GS (2005) Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 12:181–186PubMedCrossRef
22.
Zurück zum Zitat Bingley PJ (2010) Clinical application of diabetic antibody testing. J Clin Endocrinol Metab 95:25–33PubMedCrossRef Bingley PJ (2010) Clinical application of diabetic antibody testing. J Clin Endocrinol Metab 95:25–33PubMedCrossRef
23.
Zurück zum Zitat Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW (2009) Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 9:105–112PubMedCrossRef Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW (2009) Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 9:105–112PubMedCrossRef
24.
Zurück zum Zitat Myers MA, Rabin DU, Rowley MJ (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44:1290–1295PubMedCrossRef Myers MA, Rabin DU, Rowley MJ (1995) Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase. Diabetes 44:1290–1295PubMedCrossRef
25.
Zurück zum Zitat Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef Achenbach P, Lampasona V, Landherr U et al (2009) Autoantibodies to zinc transporter 8 and SLC30A8 stratify type 1 diabetes risk. Diabetologia 52:1881–1888PubMedCrossRef
26.
Zurück zum Zitat Savola K, Läärä E, Vähäsalo P et al (2001) Dynamic pattern of disease-associated autoantibodies in siblings of children with type 1 diabetes. Diabetes 50:2625–2632PubMedCrossRef Savola K, Läärä E, Vähäsalo P et al (2001) Dynamic pattern of disease-associated autoantibodies in siblings of children with type 1 diabetes. Diabetes 50:2625–2632PubMedCrossRef
27.
Zurück zum Zitat Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef Barker JM, Barriga KJ, Yu L et al (2004) Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 89:3896–3902PubMedCrossRef
28.
Zurück zum Zitat Gorus FK, Vandewalle CL, Dorchy H, van Crombrugge P, Schuit FC, Pipeleers DG (1994) Influence of age on the associations among insulin autoantibodies, islet cell antibodies, and HLA DAQ1*0301-DQB1*0302 in siblings of patients with type 1 (insulin-dependent) diabetes mellitus. Belgian Diabetes Registry. J Clin Endocrinol Metab 36:1155–1162 Gorus FK, Vandewalle CL, Dorchy H, van Crombrugge P, Schuit FC, Pipeleers DG (1994) Influence of age on the associations among insulin autoantibodies, islet cell antibodies, and HLA DAQ1*0301-DQB1*0302 in siblings of patients with type 1 (insulin-dependent) diabetes mellitus. Belgian Diabetes Registry. J Clin Endocrinol Metab 36:1155–1162
29.
Zurück zum Zitat Yu J, Yu L, Bugawan TL et al (2000) Transient antiislet autoantibodies: infrequent occurrence and lack of association with “genetic” risk factors. J Clin Endocrinol Metab 85:2421–2428PubMedCrossRef Yu J, Yu L, Bugawan TL et al (2000) Transient antiislet autoantibodies: infrequent occurrence and lack of association with “genetic” risk factors. J Clin Endocrinol Metab 85:2421–2428PubMedCrossRef
30.
Zurück zum Zitat Truyen I, de Grijse J, Weets I et al (2007) Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clin Exp Immunol 149:243–250PubMedCrossRef Truyen I, de Grijse J, Weets I et al (2007) Identification of prediabetes in first-degree relatives at intermediate risk of type I diabetes. Clin Exp Immunol 149:243–250PubMedCrossRef
31.
Zurück zum Zitat von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7:988–994CrossRef von Herrath M, Sanda S, Herold K (2007) Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 7:988–994CrossRef
32.
Zurück zum Zitat Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies: a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41:424–429PubMedCrossRef Savola K, Bonifacio E, Sabbah E et al (1998) IA-2 antibodies: a sensitive marker of IDDM with clinical onset in childhood and adolescence. Diabetologia 41:424–429PubMedCrossRef
33.
Zurück zum Zitat Decochez K, de Leeuw I, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. Diabetologia 45:1658–1666PubMedCrossRef Decochez K, de Leeuw I, Keymeulen B et al (2002) IA-2 autoantibodies predict impending type 1 diabetes in siblings of patients. Diabetologia 45:1658–1666PubMedCrossRef
34.
Zurück zum Zitat Pihoker C, Gilliam LK, Hampe CS, Lernmark Å (2005) Autoantibodies in diabetes. Diabetes 54(Suppl 2):S52–S61PubMedCrossRef Pihoker C, Gilliam LK, Hampe CS, Lernmark Å (2005) Autoantibodies in diabetes. Diabetes 54(Suppl 2):S52–S61PubMedCrossRef
35.
Zurück zum Zitat Achenbach P, Warncke K, Reiter J et al (2006) Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49:2969–2976PubMedCrossRef Achenbach P, Warncke K, Reiter J et al (2006) Type 1 diabetes risk assessment: improvement by follow-up measurements in young islet autoantibody-positive relatives. Diabetologia 49:2969–2976PubMedCrossRef
36.
Zurück zum Zitat Vehik K, Haller MJ, Beam CA et al (2011) Islet autoantibody seroconversion in the DPT-1 study. Diabetes Care 34:358–362PubMedCrossRef Vehik K, Haller MJ, Beam CA et al (2011) Islet autoantibody seroconversion in the DPT-1 study. Diabetes Care 34:358–362PubMedCrossRef
37.
Zurück zum Zitat Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet natural history study. Diabetes Care 34:1897–1901PubMedCrossRef Vehik K, Beam CA, Mahon JL et al (2011) Development of autoantibodies in the TrialNet natural history study. Diabetes Care 34:1897–1901PubMedCrossRef
38.
Zurück zum Zitat Dahlquist G, Mustonen LR (1995) Clinical onset characteristics of familial versus nonfamilial cases in a large population-based cohort of childhood-onset diabetes patients. Diabetes Care 18:852–854PubMedCrossRef Dahlquist G, Mustonen LR (1995) Clinical onset characteristics of familial versus nonfamilial cases in a large population-based cohort of childhood-onset diabetes patients. Diabetes Care 18:852–854PubMedCrossRef
39.
Zurück zum Zitat Veijola R, Reijonen H, Vähäsalo P et al (1996) HLA-DQ B1-defined genetic susceptibility, beta cell autoimmunity and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Invest 96:2489–2495CrossRef Veijola R, Reijonen H, Vähäsalo P et al (1996) HLA-DQ B1-defined genetic susceptibility, beta cell autoimmunity and metabolic characteristics in familial and nonfamilial insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. J Clin Invest 96:2489–2495CrossRef
Metadaten
Titel
An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age
verfasst von
I. Vermeulen
I. Weets
O. Costa
M. Asanghanwa
K. Verhaeghen
K. Decochez
J. Ruige
K. Casteels
J. Wenzlau
J. C. Hutton
D. G. Pipeleers
F. K. Gorus
the Belgian Diabetes Registry
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 2/2012
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2376-1

Weitere Artikel der Ausgabe 2/2012

Diabetologia 2/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.